Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Gap Inc V.GAP


Primary Symbol: GAP

The Gap, Inc. is a specialty apparel company in America. The Company offers apparel, accessories and personal care products for women, men and children. Its Old Navy, Gap, Banana Republic, and Athleta brands offer clothing, accessories and lifestyle products for men, women and children. It is an omni-channel retailer, with sales to customers both in stores and online, through Company-operated and franchise stores, websites, and third-party arrangements. Its omni-channel services, including buying online pick-up in store, order-in-store, find-in-store, and ship-from-store, as well as enhanced mobile-enabled experiences, are tailored across its collection of brands. Gap includes adult apparel and accessories, GapKids, babyGap, Gap Maternity, GapBody, and GapFit collections. Banana Republic is a premium lifestyle retailer celebrating exploration and self-expression through timeless quality, versatile fabrics, and exceptionally made womenswear, menswear, and home designs.


NYSE:GAP - Post by User

Comment by remboon Jan 02, 2011 6:47pm
448 Views
Post# 17916930

RE: Article

RE: Article I agree Schiff, it is a great read. The Quotes I love though

are:  " It’s a daunting task, but McCready says that the reason nine out of 10 products that go into the research and development cycle for health end up failing is because the science wasn’t provable. PharmaGap, with its consistent positive results for GAP-107B8, has already established it doesn’t have that problem." , and "

McInnis added that neither he nor his Stormont colleague and current PharmaGap Chairman of the Board, Rod Bryden, had any real experience with the biotech industry when they first came on board. But six years in, he is confident that the company has a drug that works." 
I do believe that in a year and a half or so PharmaGap will make a lot of people a lot of money...and oh yeah a lot of people a whole lot healthier!

<< Previous
Bullboard Posts
Next >>